Titan Biotech Campaign Aims to Help Shareholders Claim Unpaid Dividends

The "Saksham Niveshak" campaign, launched by Titan Biotech Ltd, is now running until July 9, 2026. Shareholders are urged to update their personal and bank details to claim any unpaid or unclaimed dividends before these funds are transferred to the Investor Education and Protection Fund (IEPF).

Campaign Details and Purpose

Titan Biotech is conducting its second "Saksham Niveshak – 100 Days Campaign" from April 1 to July 9, 2026. This initiative operates under a directive from the Investor's Education and Protection Fund Authority (IEPFA) and the Ministry of Corporate Affairs (MCA). The campaign's central aim is to facilitate the claiming of dividends that shareholders have not yet received.

Why This Matters for Investors

This period represents a key opportunity for shareholders to recover funds that might otherwise be permanently lost to the state's IEPF. By updating their information, investors ensure their rightful dividends are paid directly. For Titan Biotech, this campaign enhances shareholder relations and fulfills regulatory requirements for managing unclaimed sums.

Regulatory Context and Industry Trend

The IEPFA and MCA are actively promoting campaigns like this to ensure investors receive their dues. Regulations stipulate that dividends left unclaimed for seven consecutive years must be transferred to the IEPF to protect investor interests. Titan Biotech is part of a broader industry effort, with peers such as ICICI Prudential Life Insurance, Menon Bearings, Birla Corporation, and Haldyn Glass also running similar campaigns within the same timeframe. The IEPF Authority is a significant shareholder in Titan Biotech, holding 9.58% as of March 2026.

Action and Deadline

Shareholders must ensure their personal and bank details are correctly updated by the campaign's close on July 9, 2026. Failure to do so means the unpaid dividends will be transferred to the IEPF, making them difficult, if not impossible, to reclaim.

Outlook

The success of the campaign will be measured by shareholder response and the volume of dividend claims processed. Titan Biotech's ongoing commitment to investor service and regulatory compliance will also be a focus.